The study aims to assess the restoration of neurological function in patients with intractable PDN. Credit: andreas160578 from Pixabay.

Medical device company Nevro has recruited the first patient for the Painful Diabetic Neuropathy (PDN) Sensory Study.

The objective of the randomised controlled trial is to assess the restoration of neurological function in patients with intractable PDN.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Nevro CEO and president Kevin Thornal said: “The observed neurological improvements we saw in the SENZA-PDN study are unique to 10kHz Therapy and have not been reported for any other competitive SCS modality.

“Not only do we anticipate that this study will provide additional confirmatory evidence of the benefits of Nevro’s proprietary 10kHz Therapy in these PDN patients, but we also believe that the additional Level 1 data generated will be very helpful as we continue to work with payers to expand PDN coverage generally and professional societies to update PDN clinical treatment guidelines.” 

The study will involve 236 patients at multiple centres across the US. These patients will be randomly assigned to either conventional medical management or 10kHz Therapy in combination with conventional medical management.

If the criteria are met, there is an option for crossover to the other treatment arm after six months.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The PDN Sensory Study has been awarded breakthrough device designation by the US Food and Drug Administration (FDA), along with this potential device indication.

In October last year, Nevro secured approval from the FDA for its Senza HFX iQ spinal cord stimulation (SCS) system for the treatment of chronic pain.

It is developed to address the variability in pain from patient to patient and to optimise and maintain long-term pain relief, as well as improved life quality.